End-of-day quote
Korea S.E.
23:00:00 20/05/2024 BST
|
5-day change
|
1st Jan Change
|
5,550
KRW
|
-0.36%
|
|
+0.73%
|
-9.90%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
120,777
|
91,417
|
221,835
|
117,384
|
119,140
|
98,113
|
Enterprise Value (EV)
1 |
126,573
|
98,916
|
217,925
|
116,282
|
137,509
|
118,666
|
P/E ratio
|
33.3
x
|
-57.8
x
|
84.9
x
|
18.1
x
|
43.8
x
|
-19.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.71
x
|
3.54
x
|
8.39
x
|
3.44
x
|
3.19
x
|
3.01
x
|
EV / Revenue
|
3.88
x
|
3.83
x
|
8.25
x
|
3.41
x
|
3.69
x
|
3.64
x
|
EV / EBITDA
|
28.2
x
|
50.9
x
|
101
x
|
19.9
x
|
50.1
x
|
-23.7
x
|
EV / FCF
|
54.5
x
|
61.4
x
|
148
x
|
71.6
x
|
-4.84
x
|
-11
x
|
FCF Yield
|
1.83%
|
1.63%
|
0.68%
|
1.4%
|
-20.7%
|
-9.07%
|
Price to Book
|
3.86
x
|
3.03
x
|
6.62
x
|
2.85
x
|
2.69
x
|
1.9
x
|
Nbr of stocks (in thousands)
|
14,534
|
14,557
|
14,594
|
14,636
|
14,636
|
15,928
|
Reference price
2 |
8,310
|
6,280
|
15,200
|
8,020
|
8,140
|
6,160
|
Announcement Date
|
14/03/19
|
19/03/20
|
18/03/21
|
17/03/22
|
21/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
32,582
|
25,854
|
26,429
|
34,087
|
37,292
|
32,631
|
EBITDA
1 |
4,494
|
1,942
|
2,168
|
5,829
|
2,745
|
-4,998
|
EBIT
1 |
1,654
|
-130.8
|
537.5
|
4,157
|
800
|
-8,676
|
Operating Margin
|
5.08%
|
-0.51%
|
2.03%
|
12.2%
|
2.15%
|
-26.59%
|
Earnings before Tax (EBT)
1 |
4,576
|
-1,722
|
3,245
|
6,770
|
-643.9
|
-11,833
|
Net income
1 |
3,624
|
-1,582
|
2,614
|
7,114
|
2,725
|
-4,878
|
Net margin
|
11.12%
|
-6.12%
|
9.89%
|
20.87%
|
7.31%
|
-14.95%
|
EPS
2 |
249.6
|
-108.7
|
179.0
|
444.3
|
185.9
|
-316.1
|
Free Cash Flow
1 |
2,322
|
1,611
|
1,475
|
1,624
|
-28,440
|
-10,757
|
FCF margin
|
7.13%
|
6.23%
|
5.58%
|
4.76%
|
-76.26%
|
-32.97%
|
FCF Conversion (EBITDA)
|
51.66%
|
82.92%
|
68%
|
27.86%
|
-
|
-
|
FCF Conversion (Net income)
|
64.06%
|
-
|
56.42%
|
22.83%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/03/19
|
19/03/20
|
18/03/21
|
17/03/22
|
21/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
5,796
|
7,498
|
-
|
-
|
18,369
|
20,553
|
Net Cash position
1 |
-
|
-
|
3,910
|
1,102
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.29
x
|
3.86
x
|
-
|
-
|
6.693
x
|
-4.113
x
|
Free Cash Flow
1 |
2,322
|
1,611
|
1,475
|
1,624
|
-28,440
|
-10,757
|
ROE (net income / shareholders' equity)
|
10.4%
|
-4.8%
|
7.23%
|
18.3%
|
0.15%
|
-19.3%
|
ROA (Net income/ Total Assets)
|
1.68%
|
-0.13%
|
0.54%
|
3.37%
|
0.46%
|
-3.98%
|
Assets
1 |
215,509
|
1,192,931
|
481,775
|
211,377
|
589,869
|
122,662
|
Book Value Per Share
2 |
2,150
|
2,074
|
2,297
|
2,811
|
3,022
|
3,247
|
Cash Flow per Share
2 |
428.0
|
369.0
|
188.0
|
1,270
|
868.0
|
1,725
|
Capex
1 |
2,319
|
449
|
1,366
|
7,619
|
30,676
|
4,452
|
Capex / Sales
|
7.12%
|
1.74%
|
5.17%
|
22.35%
|
82.26%
|
13.64%
|
Announcement Date
|
14/03/19
|
19/03/20
|
18/03/21
|
17/03/22
|
21/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -9.90% | 65.23M | | +41.16% | 54.04B | | +43.57% | 41.96B | | -1.24% | 41.92B | | -7.59% | 28.35B | | +12.08% | 26.35B | | -22.38% | 19B | | +7.76% | 13B | | +28.88% | 12.28B | | +25.11% | 12.19B |
Other Biotechnology & Medical Research
|